As biotech deals slow, Catalio Capital amasses war chest
Valuations of public biotechnology companies have taken a hit, which is expected to depress valuations and dealmaking for privately held biotechs.
13 June 2022•6 mins read
Valuations of public biotechnology companies have taken a hit, which is expected to depress valuations and dealmaking for privately held biotechs.
Inovia hits $200m in first close for sixth early-stage fund
19 October 2026 · 4 mins read
Meet venture capital’s 2026 Women of Influence
5 October 2026 · 4 mins read
Eyeing opportunities and how the Women of Influence see trends developing
5 October 2026 · 3 mins read
Oura IPO to ring up big payday for Finnish VC Lifeline
25 September 2026 · 3 mins read
US LPs are warming to Europe: Brighteye's Ben Wirz
22 September 2026 · 7 mins read
Bain Capital Ventures closes on $1.6bn for Fund XI, targeting AI infrastructure and more
17 September 2026 · 3 mins read
Volition Capital closes on $950m for oversubscribed Fund VI
16 September 2026 · 4 mins read
